Home > Publications database > Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients. > print

001     274574
005     20240229154936.0
024 7 _ |a 10.3390/cancers15061815
|2 doi
024 7 _ |a pmid:36980700
|2 pmid
024 7 _ |a pmc:PMC10047039
|2 pmc
037 _ _ |a DKFZ-2023-00651
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Ahmed, Azaz
|0 P:(DE-He78)bac8c2c56238485ecf0475ff14438430
|b 0
|e First author
|u dkfz
245 _ _ |a Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients.
260 _ _ |a Basel
|c 2023
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1680510206_22926
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D240#LA:D240#
520 _ _ |a Mounting evidence suggests that sex plays a critical role in various aspects of cancer such as immune responses. However, a male bias exists in human and non-human studies including immunotherapy trials. The role of sex on immune responses in pancreatic ductal adenocarcinoma (PDA) is unclear.Here, tumor tissues (tumor and stroma separately) and corresponding blood samples from patients with PDA (n = 52) were systematically analyzed by immunohistochemistry and multiplex cytokine measurements and compared by sex.Females showed a stronger systemic immune response with higher levels of CXCL9, IL1B, IL6, IL10 and IL13. Additionally, more peripheral white blood cells were detected in females. In the microenvironment, males showed higher tumoral levels of CXCL12. No differences were detected in the stroma. Females showed a tendency towards an anti-tumoral immune cell profile. CXCL12 blockade indicated a differential microenvironmental effect by sex in an independent immunotherapy trial cohort of patients with PDA (one female, five males). The overall survival did not differ by sex in our cohort.Systemic and local immune responses differ between sexes in PDA. Accordingly, sex-dependent differences need to be considered in human studies and for specific immunological interventions before clinical translation.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CXCL12
|2 Other
650 _ 7 |a pancreatic cancer
|2 Other
650 _ 7 |a pancreatic ductal adenocarcinoma
|2 Other
650 _ 7 |a sex difference
|2 Other
650 _ 7 |a tumor immunology
|2 Other
700 1 _ |a Köhler, Sophia
|b 1
700 1 _ |a Klotz, Rosa
|0 0000-0003-4123-261X
|b 2
700 1 _ |a Giese, Nathalia
|b 3
700 1 _ |a Hackert, Thilo
|b 4
700 1 _ |a Springfeld, Christoph
|b 5
700 1 _ |a Jäger, Dirk
|0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
|b 6
|u dkfz
700 1 _ |a Halama, Niels
|0 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
|b 7
|e Last author
|u dkfz
773 _ _ |a 10.3390/cancers15061815
|g Vol. 15, no. 6, p. 1815 -
|0 PERI:(DE-600)2527080-1
|n 6
|p 1815
|t Cancers
|v 15
|y 2023
|x 2072-6694
909 C O |o oai:inrepo02.dkfz.de:274574
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)bac8c2c56238485ecf0475ff14438430
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-01-24T07:56:58Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-31T16:07:06Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-07-31T16:07:06Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCERS : 2022
|d 2023-10-26
920 2 _ |0 I:(DE-He78)D240-20160331
|k D240
|l Translationale Immuntherapie
|x 0
920 1 _ |0 I:(DE-He78)D240-20160331
|k D240
|l Translationale Immuntherapie
|x 0
920 1 _ |0 I:(DE-He78)D120-20160331
|k D120
|l D120 Angewandte Tumor-Immunität
|x 1
920 0 _ |0 I:(DE-He78)D240-20160331
|k D240
|l Translationale Immuntherapie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D240-20160331
980 _ _ |a I:(DE-He78)D120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21